Shared-Antigen Cancer Vaccines Keep Falling Short.

BioNTech's HPV16 mRNA vaccine BNT113 does not significantly delay head and neck cancer progression in a phase II/III trial, exemplifying challenges for shared-antigen cancer vaccines.

• Why it matters: Shared-antigen vaccines reliably generate T cells but have consistently failed to improve patient outcomes, highlighting a gap in translating immune responses into clinical benefits.
• What they did: Researchers analyzed the trial results and suggest that vaccine effectiveness depends on selecting appropriate patients and settings, and evaluating success based on overall survival rather than tumor progression.
• The result: The findings imply that focusing on overall survival and optimal patient groups may be key to realizing the potential of shared-antigen cancer vaccines.